• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025

    1/14/25 8:05:00 AM ET
    $CYTH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CYTH alert in real time by email

    Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") to be highlighted in an oral presentation

    Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced its abstracts have been accepted for oral and poster presentation at the 21st Annual WORLDSymposium™ being held February 3-7, 2025 in San Diego, CA.

    Details of the presentations are as follows:

    Oral Presentation:

    Title: Trappsol® Cyclo™: Open Label Treatment in the TransportNPC™ Sub-Study in Patients Under the Age of 3 Diagnosed with Niemann-Pick Disease Type C1

    Presenter: Ronen Spiegel, MD, Clinical Associate Professor, Director of Pediatric B Department, and Co-Director Center of Rare Disease at Emek Medical Center

    Session: Clinical Applications

    Date and Time: Thursday, February 6, 2025 at 1:30 PM PT

    Poster Presentations:

    Title: Trappsol® Cyclo™ (HPβCD) for the Long-Term Treatment of Niemann-Pick Type C1: Efficacy and Safety Data from 4 Clinical Studies and the Ongoing Expanded Access Program

    Presenter: Dr. Caroline Hastings, Pediatric hematologist oncologist, Director of Neuro-oncology, and Professor of Pediatrics at UCSF Benioff Children's Hospital Oakland

    Session: Clinical Applications & Rapid-Fire – Poster Session III

    Date and Time: Thursday, February 6, 2025 from 3:30 – 5:30 PM PT

    Title: Trappsol® Cyclo™ and NPC: Efficacy Shown Across Individual 5D Domains and Utilization of Future Assessment Tools to Demonstrate Clinically Relevant Outcomes

    Presenter: Dr. Caroline Hastings, Pediatric hematologist oncologist, Director of Neuro-oncology, and Professor of Pediatrics at UCSF Benioff Children's Hospital Oakland

    Session: Clinical Applications & Rapid-Fire – Poster Session III

    Date and Time: Thursday, February 6, 2025 from 3:30 – 5:30 PM PT

    For more information, please visit the conference website worldsymposia.org.

    About WORLDSymposium™

    WORLDSymposium™ is an annual research conference dedicated to lysosomal diseases. WORLD is an acronym that stands for We're Organizing Research on Lysosomal Diseases. Since its inception as a small group of passionate researchers in 2002, WORLDSymposium™ has grown to an international research conference that attracts over 2000 participants from more than 50 countries around the globe. For more information, please visit: worldsymposia.org.

    About Cyclo Therapeutics

    Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease. The Company's Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C1, a rare and fatal genetic disease, (NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is conducting a Phase 2b clinical trial using Trappsol® Cyclo™ intravenously in early Alzheimer's disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer's disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company's website: www.cyclotherapeutics.com.

    Safe Harbor Statement

    This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250114456775/en/

    Investor Contact:

    JTC Team, LLC

    Jenene Thomas

    (908) 824-0775

    [email protected]

    Get the next $CYTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CYTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

      NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics' shareholders representing approximately 22% of the combined company, based on the exchange ratio in the merger agreement between the parties determined to be 0.3525. Rafael also issued warrants to purchase shares of Rafael Class B common stock to certain holders of Cyclo warrants. Rafael Holdings has identified Trappsol® Cyclo™ as its lead clinical asset

      3/26/25 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

      The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo's lead clinical program Trappsol® Cyclo™ NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025. "We look forward to the upcoming shareholder vote on our pending merger with Cyclo Therapeutics (NASDAQ:CYTH) later this month and anticipate closing promptly post shareholder approvals. Upon closing, the Company's strategic focus will be on its lead clinical asset, T

      3/13/25 5:50:30 PM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)

      First data in NPC1 on treatment in this age group over a period of 48 weeks At 24 weeks of the sub-study, 7 of 8 patients (87%) and at 48 weeks of the sub-study, 6 of 7 patients (86%) show stabilization or improvement in Clinical Global Impression – Change (CGI-C) Scale Data presented at the 21st Annual WORLDSymposium™ 2025 Company on track for topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ in H1 2025 Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with rare and

      2/7/25 8:05:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CYTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group reiterated coverage on Cyclo Therapeutics with a new price target

      Maxim Group reiterated coverage of Cyclo Therapeutics with a rating of Buy and set a new price target of $25.00 from $12.00 previously

      2/10/21 8:07:06 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CYTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CYTH
    Leadership Updates

    Live Leadership Updates

    See more

    $CYTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CYTH
    SEC Filings

    See more
    • Director Conkling William was granted 27,654 shares, increasing direct ownership by 55% to 77,884 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      3/3/25 11:45:25 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wong Vivien was granted 25,140 shares, increasing direct ownership by 63% to 64,853 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      3/3/25 11:45:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Cross Shawn was granted 28,597 shares, increasing direct ownership by 27% to 136,346 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      3/3/25 11:44:36 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease

      – Dr. Hastings is a world-renowned Key Opinion Leader for Niemann-Pick Disease Type C1 and the first physician in the U.S. to use cyclodextrins for treatment in NPC, compassionate use – Site activation ongoing and currently enrolling patients in pivotal Phase 3 study, TransportNPC™ – Data seen to-date provide support for the capacity of Trappsol® Cyclo™ to stabilize disease progression with home-based intravenous infusions in NPC and demonstrate acceptable safety profile of Trappsol® Cyclo™ administered intravenously for more than 2 years Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-cha

      12/9/21 8:05:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cyclo Therapeutics Inc. (Amendment)

      SC 13G/A - Cyclo Therapeutics, Inc. (0000922247) (Subject)

      2/14/24 2:44:54 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cyclo Therapeutics Inc. (Amendment)

      SC 13G/A - Cyclo Therapeutics, Inc. (0000922247) (Subject)

      2/14/23 12:30:13 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cyclo Therapeutics Inc.

      SC 13G - Cyclo Therapeutics, Inc. (0000922247) (Subject)

      2/10/23 4:28:56 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 15-12G filed by Cyclo Therapeutics Inc.

      15-12G - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      4/7/25 4:05:19 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      3/26/25 7:05:41 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      3/24/25 4:30:22 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care